Virax Biolabs Group LtdVRAXEarnings & Financial Report
Nasdaq · Health Care · In Vitro & In Vivo Diagnostic Substances
Virax Biolabs Group Ltd is a global biotechnology company specializing in the development, production and distribution of in vitro diagnostic test kits. Its core product portfolio covers testing solutions for infectious diseases and immunological conditions, serving clinical institutions, research laboratories and commercial partners across multiple global regions.
VRAX Q2 FY2025 Key Financial Metrics
Revenue
$76.5K
Gross Profit
$10.5K
Operating Profit
$-2.7M
Net Profit
$-2.9M
Gross Margin
13.7%
Operating Margin
-3537.5%
Net Margin
-3809.4%
YoY Growth
N/A
Virax Biolabs Group Ltd Q2 FY2025 Financial Summary
Virax Biolabs Group Ltd reported revenue of $76.5K for Q2 FY2025, with a net profit of $-2.9M (-3809.4% margin). Cost of goods sold was $66.0K, operating expenses totaled $2.7M.
Key Financial Metrics
| Total Revenue | $76.5K |
|---|---|
| Net Profit | $-2.9M |
| Gross Margin | 13.7% |
| Operating Margin | -3537.5% |
| Report Period | Q2 FY2025 |
Income Statement
| Q2 2025 | |
|---|---|
| Revenue | $76500 |
| YoY Growth | N/A |
Balance Sheet
| Q2 2025 | |
|---|---|
| Assets | N/A |
| Liabilities | N/A |
| Equity | N/A |
Cash Flow
No data available for this period